Cutaneous melanoma: New advances in treatment

Anais Brasileiros de Dermatologia

Volumn 89, Issue 2, 2014, Pages 301-310

  Foletto, Michele Ceolin ^a   Haas, Sandra Elisa ^a  

^a UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

Author keywords

Antibodies; Antibody specificity; Interferons; Melanoma; Monoclonal; Therapeutics

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; CARMUSTINE; CISPLATIN; CYTOKINE; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; GLYCOPROTEIN GP 100; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; PEGINTERFERON ALPHA2B; TAMOXIFEN; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB; VINBLASTINE;

ADJUVANT THERAPY; ALOPECIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CHEMOTHERAPY; CHILL; CLINICAL TRIAL (TOPIC); CUTANEOUS MELANOMA; DRUG MEGADOSE; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEADACHE; HUMAN; IMMUNOTHERAPY; LIVER TOXICITY; MALAISE; METASTATIC MELANOMA; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SKIN MANIFESTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INDOLES; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84899438561     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20142540     Document Type: Review

References (42)

1. Koch CM. Melanoma. Oncol. 2004;27:99-101.
2. Bárzaga HOV. Caracterización clínica e histopatológica del cáncer cutáneo no melanoma. Arch Méd Camaguey. 2010;14:0-.
3. Inca. gov. br [página na internet]. Ministério da Saúde. Instituto Nacional do Câncer. Câncer de Pele Melanoma 2012 [acesso 22 Mar 2012]. Disponível em: http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/pele_melanoma/ definicao.
4. Souza RJ, Mattedi AP, Rezende ML, Corrêa Mde P, Duarte EM. An estimate of the cost of treating melanoma disease in the state of Sao Paulo-Brazil. An Bras Dermatol. 2009;84:237-43.
5. Naser N. Cutaneous melanoma-a 30-year-long epidemiological study conducted in a city in southern Brazil, from 1980-2009. An Bras Dermatol. 2011;86:932-41.
6. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1012
7. Bonfá R, Bonamigo RR, Bonfá R, Duro KM, Furian RD, Zelmanowicz Ade M. Early diagnosis of cutaneous melanoma: an observation in southern Brazil. An Bras Dermatol. 2011;86:215-21.
8. Almeida VL, Leitão A, Reina Barrett LC, Montanari CA, Donnici CL, Lopes MTP. Câncer e agentes antineoplásicos ciclo-celular específicos e ciclo-celular não específicos que interagem com o DNA: uma introdução. Quim Nova. 2005;28:118-29.
9. Rietschel P, Chapman PB. Immunotherapy of melanoma. Hematol Oncol Clin North Am. 2006;20:751-66.
10. Weeraratna AT. RAF around the edges--the paradox of BRAF inhibitors. N Engl J Med. 2012;366:271-3
11. Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res. 2012;65:9-22.
12. Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012;18:27-35.
13. Traynor K. Ipilimumab approved for metastatic melanoma. Am J Health Syst Pharm. 2011;68:768.
14. Cheng S, Koch WH, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol. 2012;29:682-8.
15. Neves AP, Vargas, M.D. Complexos de Platina(II) na Terapia do Câncer. Rev Virtual Quim. 2011;3:196-209.
16. Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5:3.
17. O'Day S, Boasberg P. Management of metastatic melanoma 2005. Surg Oncol Clin N Am. 2006;15:419-37.
18. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol. 2010;21:vii339-44.
19. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-16.
20. Wainstein AJA, Belfort, F.A. Conduta para o melanoma cutâneo. Rev Col Bras Cir. 2004;31:204-14.
21. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009;15:2123-9.
22. Norris BL, Beam, S. New Therapeutic Approaches to Metastatic Melanoma. Oncol Nurs. 2008;1:1-12.
23. Santana H, Martínez E, Sánchez JC, Moya G, Sosa R, Hardy E, et al. Molecular Characterization of Recombinant Human Interferon Alpha-2b Produced in Cuba. Biotecnol Apl. 1999;16:154-9.
24. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-58.
25. Silva CM, Viana MB, Gontijo B, Fernandes RA, Pereira LB. Giant hemangioma treated with interferon alpha-2a. J Pediatr (Rio J). 1997;73:277-80.
26. Agarwala SS, O'Day SJ. Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. Cancer Treat Rev. 2011;37:133-42
27. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117-26.
28. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366:1189-96.
29. Khayat D, Bernard-Marty C, Meric JB, Rixe O. Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol. 2002;20:2411-4.
30. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26:5748-54.
31. Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41-8.
32. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer. 2011;47:2150-7.
33. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23
34. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-64.
35. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23:177-82.
36. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
37. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19.
38. Slipicevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Ups J Med Sci. 2012;117:237-43.
39. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-65.
40. Weber JSF, Flaherty KT, Infante JR, Falchook GS, Kefford R, Daud A, et al, editors. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. ASCO Annual Meeting; 2012.
41. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327-34.
42. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904-9.